RxDoctor Payments Data

Jacqi Lambert, MD

Family Medicine · Manhattan, KSNPI 1467407569

Payments from drug & device makers

$8,513in general payments, 2019–2025

Across 555 payments — averaging $15.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • AbbVie$1K
  • Novo Nordisk$937
  • AstraZeneca$843
  • Lilly USA, LLC$792
  • Amgen$562
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$8,513100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,513 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$290,762
Medicare patients
380
Services billed
7,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol111$75,282
OzempicSemaglutide71$66,003
JardianceEmpagliflozin69$61,985
MounjaroTirzepatide45$48,448
EliquisApixaban52$37,921
RybelsusSemaglutide19$28,874
MyrbetriqMirabegron36$24,882
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$20,191
NuvigilArmodafinil11$14,532
OxycontinOxycodone Hcl11$13,659
GemtesaVibegron31$12,067
AbrysvoRsv Vacc, Pref A And Pref B/Pf32$10,249
ShingrixVaricella-Zoster Ge/As01b/Pf36$7,962
JanumetSitagliptin Phos/Metformin Hcl12$6,762
InvokanaCanagliflozin12$6,749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$937$94,87790 claims
AstraZenecaFarxiga$843$75,282111 claims
Boehringer IngelheimJardiance$304$61,98569 claims
PfizerEliquis, Abrysvo, Premarin$1,294$50,42396 claims
Lilly USA, LLCMounjaro$792$48,44845 claims
GSKTrelegy Ellipta, Shingrix, Anoro Ellipta, Arnuity Ellipta$223$35,51099 claims
Astellas Pharma US IncMyrbetriq$81$24,88236 claims
Sumitomo Pharma America, Inc.Gemtesa$68$12,06731 claims
MerckJanumet$153$6,76212 claims
Johnson & JohnsonInvokana$124$6,74912 claims
AbbVieSynthroid$1,244$1,69435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Manhattan

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →